Illumina, Inc. provided earnings guidance for fourth quarter of 2016. Fourth quarter revenue exceeded guidance, coming in at approximately $619 million. That's up $12 million sequentially and 5% year-over-year. As a result, 2016 revenue was approximately $2.4 billion, up 8% from 2015. Sequencing consumables were the star performer, growing 23% to approximately $1.3 billion. For 2017, the company expects 10% to 12% revenue growth, including modest contributions from GRAIL and Helix. GAAP EPS is expected to be $3.25 to $3.35. Non-GAAP EPS is expected to be between $3.60 and $3.70, including $0.18 of Helix dilution.